Discrepant range of sPD‐1 in different studies of chronic hepatitis B. A letter in response to Soluble programmed death‐1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B

Jeng, Wen–Juei; Yang, Hwai I.

doi:10.1111/jvh.13102

Cited by 3 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Serum sPD1 levels were greater in CHB than in controls and positively correlated with levels of ALT, AST, total bilirubin, HBV DNA, AST to platelet ratio index ((AST/upper limit of the normal AST range) X 100/platelet count), fibrosis score Fib4, hepatic inflammatory score and fibrosis but negatively correlated with platelet count 210 . As a caveat, there are assay-related issues that need to be resolved before clinical application, with additional head-to-head comparisons of the different immune assays needed to resolve discrepant sPD1 and sPDL1 levels observed in different studies 211 . …”

Section: Immunological Serum Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

Kramvis

Chang

Dandri

et al. 2022

Nat Rev Gastroenterol Hepatol

View full text Add to dashboard Cite

Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers.

show abstract

Section: Immunological Serum Biomarkersmentioning

confidence: 99%

“…As a caveat, there are assay-related issues that need to be resolved before clinical application, with additional head-to-head comparisons of the different immune assays needed to resolve discrepant sPD1 and sPDL1 levels observed in different studies 211 .…”

Section: Immunological Serum Biomarkersmentioning

confidence: 99%

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

Kramvis

Chang

Dandri

et al. 2022

Nat Rev Gastroenterol Hepatol

View full text Add to dashboard Cite

show abstract

“…The correlation between sPD-1 and clinical outcome, such as HCC, in CHB patients has been reported in several studies [20][21][22]. Nevertheless, discrepant range of sPD-1 and association results were observed among different studies which may due to different assay kits applied [23].…”

Section: Open Accessmentioning

confidence: 93%

The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays

Jeng

Chen

Wang

et al. 2022

Virol J

Self Cite

View full text Add to dashboard Cite

Background Soluble programmed death-1 (sPD-1) is a novel immune markers and possibly predictive of chronic hepatitis B (CHB) outcome. However, results were inconsistent by different ELISA kits. This study aims to compare the characteristics and correlations with other markers for sPD-1 measured by MyBioSource (MB) and R&D (RD) kits. Methods A total of 254 untreated CHB patients from three sites were assayed with sPD-1 by MB and RD kits at the same time. Spearman’s correlations between the kits, and those with viral markers and ALT levels were calculated. Multivariate linear regression analysis was applied for independent factors associated with the sPD-1 levels. Results There’s no correlation between sPD-1 level using MB and RD assays. sPD-1 by MB correlated profoundly with HBsAg (r = 0.8311, P < 0.0001), HBV DNA (r = 0.3896, P < 0.0001), and ALT levels (r = 0.1604, P = 0.0105) while an opposite trend by RD kit (r = − 0.0644, P = 0.3109; r = 0.2554, P < 0.0001; r = 0.4417, P < 0.0001, respectively for the 3 markers). In the multivariate linear regression analysis, HBsAg and ALT levels was the major factor associated with sPD-1 levels by MB and RD, respectively. Conclusions The characteristics and correlations with host/viral markers of sPD-1 by the two kits are different and leading to different associations on clinical outcomes of CHB.

show abstract

“…[17] Some evolving immunological biomarkers are currently under investigation, few notables' ones among them are; intrahepatic covalently closed circular DNA (cccDNA) and RNA, [17] serum HBsAg isoform, [18] HBV core-related antigen (HBcrAg) assessment, [19] soluble Program Death 1 (sPD1), its ligand (sPDL1) level, [20] and soluble cluster of derivatives 14 (sCD14). [21] The participants were consecutively screened for HBsAg twice with interval of at least six months duration between the two screenings. The purpose of the first screening was to determine the HBV status (seropositive or seronegative), while the second visit was aiming at determining the chronicity of the infection.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of Alpha-Fetoprotein in Staging of Chronic Hepatitis B Infection

Gloria Ayelagbe,

Suleiman,

Adekunle

et al. 2023

Rwanda J Med Health Sci

View full text Add to dashboard Cite

Background Ascertaining the stage of chronic hepatitis-B infection (CHBI) remains one of the major predicaments to effective therapeutic decision. There is pressing need to forestall dearth of such reliable biomarker(s). Despite the promising tendency of alpha-fetoprotein (AFP), it has not been assessed in staging CHBI.ObjectiveThis study was to determine the prognosis of serum AFP as a biomarker for staging CHBI. MethodsParticipants were grouped into three based on their hepatitis-B envelope antigen (HBeAg) status and alanine aminotransferase (ALT) level. By denoting HbeAg(+) as (EP), HbeAg(-) as (EN), elevated ALT as (H) and normal ALT as (I), the stages were EPH, ENH and ENI. AFP was assayed, One-way ANOVA, Multivariate linear regression and area under curve were adopted for the analysis. ResultsAFP was significantly elevated, (P < 0.05) in EPH, which equally has the highest prevalence of elevated AFP (64.7%). After adjusting for confounding factors, odds ratio was 1.438 (95% CI, 0.62–1.948), while area under the curve for predicting EPH was (0.828, 95% CI, 0.778 –0.895).ConclusionsThe finding of elevated AFP in CHBI is an independent prognostic marker of EPH. It is often associated with necroinflammation; thus, it is a reliable indicator for treatment initiation.Rwanda J Med Health Sci 2023;6(3):355-366

show abstract

Discrepant range of sPD‐1 in different studies of chronic hepatitis B. A letter in response to Soluble programmed death‐1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B

Cited by 3 publications

References 3 publications

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays

Prognostic Significance of Alpha-Fetoprotein in Staging of Chronic Hepatitis B Infection

Contact Info

Product

Resources

About